Archived Clinical Trials

  • CALGB 90401 - A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab (IND #7921, NSC #704865) In Men with Hormone Refractory Prostate Cancer (Closed to Accrual, Effective 12/21/07) - OverviewPDF document

  • ECOG 1504 - Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features (Closed to Accrual Effective December 12, 2008) - OverviewPDF document

  • ECOG 1602 - A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T cells and Helper T cells for Patients with Metastatic Melanoma (Closed to Accrual, Effective January 12, 2009) - OverviewPDF document

  • ECOG 1A05 - Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®)-Lenalidomide (Revlimid®)-Dexamethasone (VRD) versus Bortezomib (Velcade®)-Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen (Closed to Enrollment, Effective May 7, 2010) - OverviewPDF document

  • ECOG 2204 - An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely Resected Pancreatic Carcinoma (Closed to Accrual, Effective 1/9/08) - OverviewPDF document

  • ECOG 2603 - A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma (closed to accrual April 22, 2008) - OverviewPDF document

  • ECOG 2805 ASSURE - A Randomized, Double Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (Closed to Enrollment, Effective September 1, 2010) - OverviewPDF document

  • ECOG 4A03 - A Randomized Phase III Study of CC-5013 plus Dexamethasone versus CC-5013 plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone Salvage Therapy for Non-Responders (Closed to Accrual, Effective June 1, 2007)

  • ECOG 5202 - A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (Closed to Enrollment, Effective February 11, 2011) - OverviewPDF document

  • ECOG 5204 - Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation (Closed to Accrual, Effective April 29, 2009) - OverviewPDF document

  • ECOG E2Z04 - Quality of Life in Younger Breast Cancer Survivors (Closed to Accrual, Effective December 23, 2008)

  • ECOG JMA17 - A Phase III Randomized Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen (Closed to Accrual on May 8, 2009) - OverviewPDF document

  • ECOG PACCT-1 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial (Closed to Registration, Effective October 6, 2010) - OverviewPDF document

  • ECOG SWOG 9346 - Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III (Closed to Accrual Effective September 1, 2008) - OverviewPDF document

  • Fox Chase 94-016 - Genetic Research Studies in Sporadic, Familial and Hereditary Forms of Cancer

  • Fox Chase FER-GU-004 - Phase II Trial of Cetuximab With and Without Weekly Paclitaxel in Patients with Previously Treated Advanced Urothelial Cancer - OverviewPDF document

  • GOG 0209 - Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer (Closed to Accrual) - OverviewPDF document

  • GOG 0218 - A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC#704865, IND #7921) Followed By Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III (Suboptimal) and All Stage IV, Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Cancer (Temporarily Closed to Accrual) - OverviewPDF document

  • NCCTG N0147 - A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer (Permanently Closed to Accrual) - OverviewPDF document

  • NCCTG N0723 - A Phase III Biomarker Validation Study of Second-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib (Closed to Accrual) - OverviewPDF document

  • NSABP B-42 - A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer (Closed to Enrollment) - OverviewPDF document

  • NSABP R-04 - A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-FU with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum (Closed to Enrollment, Effective August 16, 2010) - OverviewPDF document

  • PrECOG PrE0501 - A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination with Docetaxel and Carboplatin ± Placebo or Maintenance Therapy with Vandetanib in Patients with IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) - OverviewPDF document

  • RTOG 0212 - A Phase II/III Randomized Trial of Two Doses (Phase III- Standard vs. High) and Two High Dose Schedules (Phase II-Once vs. Twice Daily) For Delivering Prophylactic Cranial Irradiation for Patients with Limited Disease Small Cell Lung Cancer (Closed to Accrual, Effective February 12, 2008) - OverviewPDF document

  • RTOG 0320 - A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone versus with Temozolomide or Erlotinib in Patients with Non-Small Cell Lung Cancer and 1-3 Brain Metastases - OverviewPDF document

  • RTOG 0522 - A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas (Closed to Accrual) - OverviewPDF document

  • RTOG 0614 - Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy (Closed to Accrual, Effective December 17, 2008) - OverviewPDF document

  • SWOG S0325 - A Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) In Chronic Phase (Closed to Accrual Effective February 28, 2009) - OverviewPDF document

  • SWOG S0600 - Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab With or Without Bevacizumab As Second-Line Therapy for Patients With Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX (Closed to Enrollment, Effective November 10, 2010) - OverviewPDF document

  • Wyeth 3144A2-3003-WW - A Phase 3, Randomized, Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2-Positive Locally Advanced or Metastatic Breast Cancer - OverviewPDF document

© Copyright 2012, Meridian Health, Inc. | 732-741-2700

Riverview Medical Center | 1 Riverview Plaza, Red Bank, NJ 07701